Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Abdula Kurkayev is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, Nannette Holloman. The prosecution is active in 1 distinct art unit, which suggests a very specific technical focus for the current pending application.
Nannette Holloman is the busiest examiner for the portfolio, currently overseeing 1 pending office action. Because there is only 1 pending office action and 1 distinct examiner, the entire current prosecution effort is focused on this single interaction. This allows for a dedicated and precise response to the issues raised in the Biotechnology & Pharmaceuticals area within the 1 distinct art unit.
For a patent practitioner, the 1 pending office action in 1 distinct art unit means that the outcome depends entirely on the 1 distinct examiner. There is no other pending activity to provide context or alternative strategies within the office. Success in this portfolio requires a thorough understanding of Nannette Holloman's specific requirements and the standards of the 1 distinct art unit for this single matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLOMAN, NANNETTE | 1 | 60.8% | +23.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18768997 | METHOD OF OBTAINING STABLE SUSPENSIONS OF HETEROCRYSTALS OF TITANIUM DIOXIDE OR PARTICLES OF SILICON DIOXIDE AND STABLE SUSPENSIONS OBTAINED BY THIS METHOD FOR INITIATION OF ACTIVE FORM OF OXYGEN IN BODY AT USE IN MEDICAL FORMS | HOLLOMAN, NANNETTE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18768997 | METHOD OF OBTAINING STABLE SUSPENSIONS OF HETEROCRYSTALS OF TITANIUM DIOXIDE OR PARTICLES OF SILICON DIOXIDE AND STABLE SUSPENSIONS OBTAINED BY THIS METHOD FOR INITIATION OF ACTIVE FORM OF OXYGEN IN BODY AT USE IN MEDICAL FORMS | HOLLOMAN, NANNETTE | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18768997 | METHOD OF OBTAINING STABLE SUSPENSIONS OF HETEROCRYSTALS OF TITANIUM DIOXIDE OR PARTICLES OF SILICON DIOXIDE AND STABLE SUSPENSIONS OBTAINED BY THIS METHOD FOR INITIATION OF ACTIVE FORM OF OXYGEN IN BODY AT USE IN MEDICAL FORMS | HOLLOMAN, NANNETTE | 1612 | §103§112 | Non-Final OA | — | Pending | Jul 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAbdula Kurkayev has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Nannette Holloman has the most, with 1 of Abdula Kurkayev's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.